Autonomix Medical, Inc.

Autonomix Medical, Inc.

NNASDAQ:AMIX
1.10
USD
-0.27
(-19.71%)
-17.07EPS
7.51MMarket Cap
Mar 03Next Earn
Autonomix Medical, Inc.
NASDAQ:AMIX
(Nasdaq Stock Market)

Recent

price

1.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2023
2024
2025
2026
TTM
USD
- -
- -
- -
- -
- -
Revenue per Share
-39.58
-311.27
-135.65
-48.64
-17.07
Basic EPS, GAAP
-36.87
-134.53
-98.34
-35.77
-17.43
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
12.81
170
68.11
10.85
3.54
Book Value per Share
12.81
170
68.11
10.85
3.54
Tangible Book Value per Share
- -
- -
- -
- -
1
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
-2
-15
-11
-17
-12
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
1
9
8
6
7
Working Capital
- -
1
- -
- -
- -
LT Debt
1
8
8
6
7
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-372.97
-145.1
-238.89
-176.02
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
2
Market Capitalization
4
3
8

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
Total Current Assets
8
4
8
Cash, Cash Equivalents & STI
7
3
8
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-27.21%
Free Cash Flow
- -
- -
48.6%
Net Income, GAAP
- -
- -
46.49%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-46.25
-47.76
-30.75
-26.84
-135.65
2026
-22.69
-28.91
-7.65
-4.91
-48.64
2027
-5.02
-2.51
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Business
Autonomix Medical, Inc. is a medical device company specializing in the development and commercialization of precision nerve-targeted therapies to transform the treatment of peripheral nervous system diseases. The company’s core products include a proprietary platform that utilizes precision guidance technology combining nerve sensing and radio frequency (RF) ablation to sense, treat, and verify nerve signaling through a minimally invasive, transvascular procedure. This platform initially targets severe pain associated with pancreatic cancer and aims to provide rapid, effective, and durable pain relief while enabling significant opioid reduction in patients. Autonomix leverages this first-in-class platform technology across multiple potential therapeutic areas including chronic pain management, hypertension, cardiology, pulmonology, and gastroenterology. The company’s technology is protected by an extensive intellectual property portfolio encompassing over 120 issued or pending patents globally. Founded in 2009 and headquartered in The Woodlands, Texas, Autonomix operates primarily in the United States while advancing global clinical development. Recent major developments include successful progression through a first-in-human proof-of-concept clinical study that demonstrated sustained, clinically meaningful improvements in quality of life and pain reduction for pancreatic cancer patients. This study underpins the company’s planned multicenter pivotal clinical trial in the U.S. set to begin in 2026, supporting its regulatory pathway toward a De Novo FDA classification expected by 2027. Autonomix also commenced a Good Laboratory Practice (GLP) preclinical study for its combined sensing and ablation system and has raised over $15 million through private placements and public offerings during 2024 and 2025 to fund ongoing clinical and regulatory activities. The company is expanding its pipeline beyond pancreatic cancer, exploring applications in cardiovascular, pulmonary, and chronic pain indications. Autonomix maintains active clinical site agreements and strategic partnerships to support its clinical trial execution and is highlighted frequently in scientific conferences to showcase its innovative technology and clinical progress.

Company News

  • Autonomix Highlights Renal Denervation Strategy and Vision for Illuminating the Nervous System at TCT 2026

  • Autonomix Medical Granted New U.S. Patent Strengthening Proprietary Catheter-Based Sensing Technology

  • Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation

  • Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance

  • Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform

  • Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors

  • Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

  • Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

  • Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

  • Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

  • Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award

  • Autonomix Stock Skyrockets After Obtaining Key Cancer Tech Patent

  • Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy

  • Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study

  • Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study

  • Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform

  • Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform

  • Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

  • Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

  • Autonomix Medical wins new patent for neural sensing technology